NAV3 Is a Novel Prognostic Biomarker Affecting the Immune Status of the Tumor Microenvironment in Colorectal Cancer.

J Immunol Res · 2022 · PMC9262578 · PMID 35812247

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a possible trendno p-value reported

However, we can observe a possible trend of higher ImmuneScore displaying a poor prognosis in CRC patients.

also in 1,410 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.